Phase I clinical results with MLN518, a novel FLT3 antagonist: Tolerability, pharmacokinetics, and pharmacodynamics.

被引：0
|
作者：
De Angelo, DJ
Stone, RM
Bruner, RJ
Caligiuri, MA
Heaney, ML
Nimer, SD
Paquette, R
Sawyers, CL
Lambing, JL
Lokker, NA
Giese, NA
Sinha, V
Cooper, MR
Druker, BJ
Heinrich, MC
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Ohio State Comprehens Canc Ctr, Columbus, OH USA
[3] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[4] Univ Calif Los Angeles, Ctr Med, Los Angeles, CA 90024 USA
[5] Millennium Pharmaceut Inc, Cambridge, MA USA
[6] Oregon Hlth Sci Univ, Portland, OR USA
来源：
BLOOD | 2003年 / 102卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
219
引用
收藏
页码：65A / 66A
页数：2
相关论文
共 50 条
  • [31] Preliminary Analysis Results of a Phase I Study of the FLT3 Inhibitor SKLB1028 in Patients with Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia
    Liu, Ting
    Zhu, Huanling
    Yao, Xuekun
    Peng, Yueying
    Wang, Yumei
    Zhan, Guoning
    Yuan, Jing
    Ni, Shaonan
    Qiao, Jie
    Hu, Zijian
    Lyu, Cheng
    BLOOD, 2019, 134
  • [32] Safety, tolerability and pharmacokinetics of single and multiple doses of a novel sigma-1 receptor antagonist in three randomized phase I studies
    Abadias, Montserrat
    Escriche, Marisol
    Vaque, Anna
    Sust, Mariano
    Encina, Gregorio
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2013, 75 (01) : 103 - 117
  • [33] OCE-205, A Novel, Selective Vasopressin Receptor Mixed Agonist-Antagonist: Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics from a Phase 1 Study in Healthy Volunteers
    Bagger, Yu
    Ravis, William R.
    Harris, Geoff
    Bukofzer, Stan
    CLINICAL DRUG INVESTIGATION, 2023, 43 (09) : 709 - 717
  • [34] OCE-205, A Novel, Selective Vasopressin Receptor Mixed Agonist-Antagonist: Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics from a Phase 1 Study in Healthy Volunteers
    Yu Bagger
    William R. Ravis
    Geoff Harris
    Stan Bukofzer
    Clinical Drug Investigation, 2023, 43 : 709 - 717
  • [35] INTERIM RESULTS OF PHASE 1 AND 2 TRIALS TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND CLINICAL ACTIVITY OF BION-1301 IN PATIENTS WITH IGA NEPHROPATHY
    Barratt, Jonathan
    Hour, Billy
    Sibley, Cailin
    Mittan, Angelique
    Roy, Suzanne
    Stromatt, Colleen
    Endsley, Aaron
    Lo, Jeannette
    Glicklich, Alan
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2021, 36
  • [36] Safety, Tolerability and Pharmacokinetics of Bencycloquidium Bromide, a Novel Inhaled Anticholinergic Bronchodilator, in Healthy Subjects: Results from Phase I Studies
    Luo, Zhu
    Hu, Chao
    Pan, Yuanyuan
    Miao, Jia
    Wang, Ying
    Ding, Li
    Liang, Maozhi
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2021, 157
  • [37] Novel long-acting ropeginterferon alfa-2b: Pharmacokinetics, pharmacodynamics and safety in a phase I clinical trial
    Huang, Yi-Wen
    Qin, Albert
    Fang, Jane
    Wang, Ting-Fang
    Tsai, Chung-Wei
    Lin, Ko-Chung
    Teng, Ching-Leou
    Larouche, Richard
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2022, 88 (05) : 2396 - 2407
  • [38] An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients
    O'Farrell, AM
    Foran, JM
    Fiedler, W
    Serve, H
    Paquette, RL
    Cooper, MA
    Yuen, HA
    Louie, SG
    Kim, H
    Nicholas, S
    Heinrich, MC
    Berdel, WE
    Bello, C
    Jacobs, M
    Scigalla, P
    Manning, WC
    Kelsey, S
    Cherrington, JM
    CLINICAL CANCER RESEARCH, 2003, 9 (15) : 5465 - 5476
  • [39] OCE-205, A NOVEL, SELECTIVE VASOPRESSIN (V1a) RECEPTOR MIXED AGONIST-ANTAGONIST: SAFETY, TOLERABILITY, AND PHARMACOKINETICS/PHARMACODYNAMICS FROM A PHASE 1 STUDY
    Blemings, Allan
    Bagger, Yu
    Ravis, William R.
    Harris, Geoff
    HEPATOLOGY, 2022, 76 : S1142 - S1143
  • [40] UPDATED INTERIM RESULTS OF A PHASE 1/2 STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS AND CLINICAL ACTIVITY OF BION-1301 IN PATIENTS WITH IGA NEPHROPATHY
    Barratt, Jonathan
    Kooienga, Laura
    Hour, Billy
    Agha, Irfan
    Schwartz, Brian
    Sorensen, Bess
    Lo, Jeannette
    King, Andrew
    Sathaliya, Taher
    Iyer, Sai Prasad N.
    Endsley, Aaron
    Glicklich, Alan
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2022, 37 : I145 - I145
12345